SINTX Technologies (SINT) investor relations material

Material innovation and technology

• Developed silicon nitride as a novel biomaterial for medical implants, offering superior infection resistance and bone integration compared to titanium and PEEK.

• Silicon nitride elutes nitrogen molecules that kill bacteria and viruses without causing antibiotic resistance.

• Demonstrated enhanced osteoblast activity and wound healing with silicon nitride, outperforming traditional materials.

• Created silicon nitride-PEEK composites to combine mechanical properties of PEEK with biological benefits of silicon nitride.

• Developed coating technology to apply silicon nitride to metal implants for broader application.

Market strategy and product development

• Targeting the extremities segment, especially foot and ankle, due to high growth rates and unmet needs.

• Launched a 100% silicon nitride foot and ankle wedge system, receiving FDA clearance in fall and starting limited user release.

• Secured verbal commitments from 71 surgeons for product adoption, with full launch planned for Q4.

• Plans to expand into patient-specific implants for large bone defects in lower and upper extremities.

• Developing custom instrumentation and single-use cutting guides to accompany implants.

Competitive positioning and partnerships

• Only three companies globally can launch patient-specific extremity implants; unique in using silicon nitride.

• Silicon nitride enables claims for use in active infection cases, a niche not addressed by competitors.

• Partnership with Evonik to produce silicon nitride-PEEK compounds, validating technology and expanding reach.

• Robust patent portfolio and proprietary manufacturing create high barriers to entry.